CancerOne in two Australians will be diagnosed with cancer during their lifetime. Most anti-cancer drugs are cytotoxic with significant side effects. Highly selective drugs with minimal toxicity are critically needed.

DDB's studies investigate the tumour microenvironment as a novel therapeutic target. We study the peripheral nervous system and its capacity to regulate key tumour processes, including metastasis, inflammation, angiogenesis and hypoxia.

We are evaluating drugs that interact with the peripheral nervous system as novel strategies to limit cancer progression, and working with medicinal chemists to design and evaluate new anti-cancer compounds.

Lab head

Lab name

Research areas

Dr Michelle L Halls

GPCR signalosomes and compartmentalization

protein complexes, signal compartmentalisation, spatiotemporal signalling, cAMP, ERK, receptor trafficking, cancer

Dr Erica Sloan

Neural Regulation of Cancer

cancer, stress, symptoms, treatment, metastasis, molecular and cellular mechanisms, imaging, behaviour, mouse models

Dr Sab Ventura

Male reproductive pharmacology

male contraception, benign prostatic hyperplasia, prostate cancer, vas deferens, adrenoceptors, purinoceptors